SCHEMBL2711302

SCHEMBL2711302

Clc1ccc(C2CCNCC2)cc1Cl

nearest known ligand 0.64

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 10/20 0.64
SLC6A4 P31645 10/20 0.64
SLC6A3 Q01959 10/20 0.64
KCNH2 Q12809 5/20 0.64
CYP2D6 P10635 4/20 0.64
QDPR P09417 1/20 0.56
HTR2C P28335 5/20 0.50
SLC18A3 Q16572 1/20 0.50
SIGMAR1 Q99720 1/20 0.50
HTR3A P46098 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2160176 0.98 SLC6A2 (0.62) SLC6A2SLC6A4SLC6A3KCNH2CYP2D6
SCHEMBL1823096 0.89 SLC6A2 (0.81) SLC6A2SLC6A4SLC6A3KCNH2CYP2D6
SCHEMBL13093036 0.89 SLC6A2 (0.81) SLC6A2SLC6A4SLC6A3KCNH2CYP2D6
Hydrochloric Acid SCHEMBL27410631 0.87 SLC6A2 (0.78) SLC6A2SLC6A4SLC6A3KCNH2CYP2D6
SCHEMBL9870878 0.85 SLC6A2 (0.58) SLC6A2SLC6A4SLC6A3KCNH2CYP2D6
SCHEMBL5585044 0.83 SLC6A2 (0.58) SLC6A2SLC6A4SLC6A3KCNH2CYP2D6
SCHEMBL5584982 0.83 SLC6A2 (0.58) SLC6A2SLC6A4SLC6A3KCNH2CYP2D6
SCHEMBL3384929 0.83 SLC6A2 (0.56) SLC6A2SLC6A4SLC6A3KCNH2CYP2D6
SCHEMBL3383243 0.83 QDPR (0.51) SLC6A2SLC6A4SLC6A3KCNH2CYP2D6
SCHEMBL31342377 0.83 QDPR (0.51) SLC6A2SLC6A4SLC6A3KCNH2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104024251-B Benzenesulfonamide compounds and their use as therapeutic agents 克赛农制药股份有限公司 2017-08-11 CN claimed
EP-1963268-B1 DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION NSAB AF NEUROSEARCH SWEDEN AB (DK) 2010-12-01 EP claimed
US-20080269286-A1 Disubstituted Phenylpiperidines as Modulators of Cortical Catecholaminergic Neurotransmission NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2008-10-30 US claimed
EP-1963268-A1 DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION Neurosearch Sweden AB (SE) 2008-09-03 EP claimed
WO-2007065655-A1 DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION NEUROSEARCH SWEDEN AB (SE) 2007-06-14 WO claimed
US-20240018119-A1 CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2024-01-18 US disclosed
US-20240018119-A1 CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2024-01-18 US disclosed
EP-3463357-B1 (2S)-1-[4-(3,4-DICHLOROPHENYL)PIPERIDIN-L-YL]-3-[2-(5-METHYL-L,3,4-OXADIAZOL-2-YL)BENZO[B]FURAN-4-YLOXY]PROPAN-2-OL OR ITS METABOLITE FOR TREATING ANXIETY DISORDERS MINERVA NEUROSCIENCES INC (US) 2023-09-20 EP disclosed
CN-110498789-B Aralkyl piperidine derivative and application thereof in multi-target anti-depression 上海医药工业研究院 2022-04-05 CN disclosed
WO-2021241876-A1 CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS 재단법인 대구경북첨단의료산업진흥재단 2021-12-02 WO disclosed
CN-108358936-A Piperazine ketone compounds containing piperidine ring and its preparation method and application 山东大学 2018-08-03 CN disclosed
CN-104024251-B Benzenesulfonamide compounds and their use as therapeutic agents 克赛农制药股份有限公司 2017-08-11 CN disclosed
EP-0580398-B1 Carbamoyl pyrrolidone derivatives for the treatment of depression and cerebrovascular disorders SHIONOGI & CO (JP) 1999-11-24 EP disclosed
US-5321035-A Antiserotonin, antiischemic agents SHIONOGI & CO., LTD. (JP) 1994-06-14 US disclosed
EP-0580398-A1 Carbamoyl pyrrolidone derivatives for the treatment of depression and cerebnovascular disorders SHIONOGI & CO., LTD. (JP) 1994-01-26 EP disclosed
EP-0518939-A1 ANTIARRHYTHMIC AGENTS BTG INTERNATIONAL LIMITED (GB) 1992-12-23 EP disclosed
WO-1991013865-A1 ANTIARRHYTHMIC AGENTS ISIS INNOVATION LIMITED (GB) 1991-09-19 WO disclosed
US-4077958-A ANTIDEPRESSANTS E. R. SQUIBB & SONS, INC. (US) 1978-03-07 US disclosed
US-4007191-A ANTIDEPRESSANT E. R. SQUIBB & SONS, INC. (US) 1977-02-08 US disclosed
US-3935227-A ANTIDEPRESSANTS, ANTIANXIETY, ANTIINFLAMMATORY AGENTS E. R. SQUIBB & SONS, INC. (US) 1976-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269286-A1 Disubstituted Phenylpiperidines as Modulators of Cortical Catecholaminergic Neurotransmission SLC6A2, SLC18A2, PNMT SLC6A2 1/4885SLC6A4 15/4885SLC6A3 4/4885
US-20240018119-A1 CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS MAOA, DRD2, MAOB SLC6A2 4/4885SLC6A4 23/4885SLC6A3 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.